Polyrizon agreement with Eurofins secures CTM for PL-14 allergy blocker trial

Polyrizon (PLRZ) previously announced that it entered into a manufacturing agreement with Eurofins CDMO Amatsiaquitaine, a leading European-based Good Manufacturing Practice manufacturer. This collaboration will supply Clinical Trial Material, or CTM, for Polyrizon’s PL-14 allergy blocker, in preparation for a clinical trial that is expected to commence in 2025. With this agreement, which was announced earlier this month, Polyrizon secures a reliable and compliant manufacturing source for the PL-14 clinical trial. The trial aims to evaluate the safety and efficacy of PL-14 as an allergy blocker, advancing Polyrizon’s mission to address allergy-related health issues through unique nasal sprays.